Physician profile
Ty C Ward
NPI 1932183415
$2,281.27
in general payments reported to CMS, 2019-2025
22 companies · $821 in 2025
The $821 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $196 · 2023: $422 · 2024: $670 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.05 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $522.45 | 2021-2025 | |
| Axsome Therapeutics, INC. | $311.66 | 2022-2025 | Auvelity |
| Indivior INC. | $209.48 | 2023-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $168.61 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $140.18 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $133.20 | 2024-2025 | Fanapt |
| Abbott Laboratories | $130.78 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $113.77 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $103.53 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $95.59 | 2023-2025 | Uzedy, Austedo Xr |
| Braeburn INC. | $76.20 | 2023-2025 | Brixadi |
| Glaxosmithkline, LLC. | $42.91 | 2021-2022 | |
| Lundbeck LLC | $40.31 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $37.51 | 2021-2022 | |
| Tris Pharma INC | $35.83 | 2024-2025 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $28.45 | 2021 | |
| Hikma Pharmaceuticals USA | $21.00 | 2023 | Kloxxado |
| Lilly USA, LLC | $16.80 | 2021 | |
| Novo Nordisk INC | $15.48 | 2022 | |
| Pfizer INC. | $15.08 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.36 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ty Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.